Focus Select® Citrus Chewable
Providing essential vitamins and minerals to support macular health.*
- Tasty Citrus Flavor
- Safer For More Patients
About Select Chewable
We believe our #1 physician recommended supplement is the safest and most effective formulation to support ocular health.*
Focus Select® Chewable utilizes the latest improvements discovered in AREDS2®, replacing beta-carotene with lutein and zeaxanthin and limiting zinc to the lowest dosage proven effective in the study. Our unique formulation not only provides powerful levels of the nutrients proven to be beneficial in AREDS2®, it is safer for smokers and reduces the risk of side effects associated with higher levels of zinc.
Focus Select® Chewable is produced in an NSF certified and FDA audited facility. As an extra measure, we conduct and approve a third-party certification of analysis for every active ingredient, on every lot, every time.
Ask your eye doctor if Focus Select® Chewable is the best choice for you.
AREDS® and AREDS2® are registered trademarks of the US Department of Health and Human Services, which is not affiliated with Covalent Medical, LLC or this website.
Safe and Effective Zinc Levels
Safe and effective Zinc levels.
Our physicians apply a “first do no harm” dictim when formulating our products by carefully assessing risks versus benefits. Because taking too much zinc is known to cause side effects in some patients such as nausea, stomach discomfort, and urinary tract complications, our developers chose the lowest zinc dose proven effective in the AREDS2 study.
Safeguarding Your Health
Safeguarding your health.
Our physician founders recognize that the science around nutrition has outpaced regulation. Because the FDA isn’t authorized to review dietary supplement for safety and effectiveness before they are marketed, physicians are the most trusted professionals for determining a supplement’s safety. We take this responsibility seriously from formula development to manufacturing to the way our supplements are distributed.
Discover how our formulas are developed with your safety in mind.
- Serving Size: 1 Chewable Tablet (2 times per day)
- Servings Per Container: 180
Take one (1) tablet in the morning and one (1) tablet in the evening with meals. Read warnings and only use as directed.
Sugar, natural flavors, hydroxypropyl cellulose, stearic acid, citric acid, turmeric root extract (for color), magnesium stearate, silica and sucralose.
How was the Focus Select® formulation developed?
Focus Select is based on peer-reviewed findings and analysis of the Age-Related Eye Disease Studies (AREDS) conducted by the National Eye Institute (NEI), a division of the National Institute of Health.
In 1992, the National Eye Institute launched the large-scale AREDS study to investigate the impact of supplementation on patients with AMD. The 2001 findings demonstrated that high doses of antioxidant vitamins and minerals slowed the progression of AMD in people with intermediate AMD and those with Advanced AMD in one eye by an average of 25% over a five-year period.
Original AREDS formulation:
- 500 mg of vitamin C
- 400 international units of vitamin E
- 15 mg beta-carotene
- 80 mg zinc oxide
- 2 mg copper as cupric oxide
AREDS2 was a follow-up study conducted to in effort to improve upon the original formula. The original AREDS contained beta-carotene, an antioxidant found to be associated with an increased risk of lung cancer in smokers in two large trials funded by the National Cancer Institute. The original formula also contained 80 mg of zinc, a level considered too high by some nutritionists and which is associated with side effects in some patients.
Modifications tested in AREDS2:
- 10 mg of lutein and 2 mg zeaxanthin
- 1000 mg omega-3 fatty acids
- Removing beta-carotene
- Reducing zinc levels to 25 mg
AREDS2 findings impacting supplementation:
- Replacing the antioxidant beta-carotene with lutein and zeaxanthin in the AREDS2 trial resulted in a slight reduction in risk of advanced AMD compared to the original AREDS with beta-carotene
- Adding Omega-3 fatty acids did not improve the risk of advanced AMD overall
- Lowered zinc levels were found to be as effective as the original formulation
Why does the Focus Select® formula contain 25 mg of zinc?
In the second AREDS study NEI investigators discovered that 25 mg of zinc was equally as effective as 80 mg in reducing the progression of AMD. The original study’s 80 mg level of zinc was thought to be too high by some nutritionists. Additionally, consumption of too much zinc is known to have side effects such as nausea, stomach pains, and an increased risk of urinary tract problems such as infections and kidney stones. For this reason, the developers of Focus Select chose the lowest dose of zinc proven effective.
Who should take Focus Select®?
Focus Select should only be considered by those at risk for developing advanced AMD. Prior to taking the levels of vitamins and minerals found in our formula, patients should speak with their doctor about the risk of developing advanced AMD and whether taking Focus Select is right for them.
Will taking Focus Select® cure AMD?
No. There are currently no treatments for dry AMD. While the AREDs formulations may slow the progression of dry AMD in people with moderate levels of disease by 25%, no supplement has demonstrated the ability to improve or restore vision.
Can patients take a daily multivitamin if they are taking Focus Select®?
Yes. Most people in the AREDS studies also took multivitamins. However, you should first consult with your primary care doctor and receive their approval to take a multivitamin in conjunction with Focus Select.
Can patients take a daily multivitamin instead of Focus Select®?
No. While a multivitamin has a broad spectrum of vitamins and minerals, it does not contain the high levels of specific antioxidants proven to be effective in the AREDS2 study.
Should patients consider changing to Focus Select® if they are on an original AREDS formula?
Yes. Replacing beta-carotene with lutein/zeaxanthin is safer for smokers and showed a lower risk of progression (18%) of AMD in AREDS subjects compared with those in the AREDS2 trial. Additionally, the 25 mg dose of zinc in lieu of 80 mg may prevent side common side effects associated with zinc.